Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy

American Journal of Psychiatry

Volumn 157, Issue 12, 2000, Pages 1973-1979

  Rickels, K ^a   DeMartinis, N ^a   Garcia Espana, F ^a   Greenblatt, D J ^a   Mandos, L A ^a   Rynn, M ^a  

^a The Science Center Philadelphia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DIAZEPAM; IMIPRAMINE; LORAZEPAM; PLACEBO;

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BENZODIAZEPINES; BUSPIRONE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIPRAMINE; MALE; PLACEBOS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0033672991     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.157.12.1973     Document Type: Article

References (33)

1. Use of benzodiazepines in anxiety disorders
2. Clinical uses of benzodiazepines
3. Long-term therapeutic use of benzodiazepines, I: Effects of abrupt discontinuation
4. Long-term therapeutic use of benzodiazepines, II: Effects of gradual taper
5. Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder
6. Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder
7. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy: Effects of withdrawal severity and outcome
8. Trazodone in benzodiazepine dependence
9. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal symptoms and taper outcome
10. Imipramine and chlordiazepoxide in depressive and anxiety disorders, II: Efficacy in anxious outpatients
11. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone and diazepam
12. Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression
13. Long-term treatment of anxiety and risk of withdrawal: Prospective comparison of clorazepate and buspirone
14. Entry of diazepam and its major metabolite into cerebrospinal fluid
15. Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography: Use in pharmacokinetic studies of lorazepam
16. Automated gas chromatographic determination of plasma alprazolam concentrations
17. Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection: Application to single-dose pharmacokinetic studies
18. The Hopkins Symptom Checklist (HSCL): A measure of primary symptom dimensions
19. Length of treatment with anxiolytic sedatives and response to their sudden withdrawal
20. Plasma alprazolam concentrations: Relation to efficacy and side effects in the treatment of panic disorder
21. Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy
22. Evaluating clinical improvement in anxious outpatients: A comparison of normal and treated neurotic outpatients
23. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms
24. Progesterone coadministration in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and taper outcome
25. A controlled trial of ondansetron, a 5-H3 antagonist, in benzodiazepine discontinuation
26. Increase of noradrenaline release in the hypothalamus of freely moving rats by postsynaptic 5-hydroxytryptamine 1A receptor activation
27. Diazepam alters brain 5-HT function in man: Implications for acute and chronic effects of benzodiazepines
28. A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms
29. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: A placebo-controlled, double-blind study
30. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients
31. Long-term benzodiazepine users: 3 Years after participation in a discontinuation program